These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24867124)

  • 1. Reasons for nonadherence to tamoxifen and aromatase inhibitors for the treatment of breast cancer: a literature review.
    Sawesi S; Carpenter JS; Jones J
    Clin J Oncol Nurs; 2014 Jun; 18(3):E50-7. PubMed ID: 24867124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to long-term adjuvant hormonal therapy for breast cancer.
    Gotay C; Dunn J
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-15. PubMed ID: 22098287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to endocrine therapy for breast cancer.
    Chlebowski RT; Geller ML
    Oncology; 2006; 71(1-2):1-9. PubMed ID: 17344666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Endocrine Therapy Nonadherence, Adverse Effects, Decisional Support, and Decisional Needs in Women With Breast Cancer.
    Milata JL; Otte JL; Carpenter JS
    Cancer Nurs; 2018; 41(1):E9-E18. PubMed ID: 27532743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy.
    Hadji P
    Crit Rev Oncol Hematol; 2010 Feb; 73(2):156-66. PubMed ID: 19299162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry.
    Stanton AL; Petrie KJ; Partridge AH
    Breast Cancer Res Treat; 2014 Jun; 145(2):525-34. PubMed ID: 24781972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging bone health issues in women with breast cancer in Hawai'i.
    Carney JF; Davis J
    Hawaii Med J; 2007 Jun; 66(6):164-6. PubMed ID: 17621865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant radiation and tamoxifen.
    Freedman GM; Anderson P; Li T; Ross E; Swaby R; Goldstein L
    Cancer; 2006 Dec; 107(11):2552-8. PubMed ID: 17061250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging role of the new aromatase inhibitors in the treatment of breast cancer.
    Sulkes A
    Isr Med Assoc J; 2005 Apr; 7(4):257-61. PubMed ID: 15847208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
    Poole R; Paridaens R
    Curr Opin Oncol; 2007 Nov; 19(6):564-72. PubMed ID: 17906453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on aromatase inhibitors in breast cancer.
    Gould RE; Garcia AA
    Curr Opin Obstet Gynecol; 2006 Feb; 18(1):41-6. PubMed ID: 16493259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention.
    Lin JH; Zhang SM; Manson JE
    Cancer Prev Res (Phila); 2011 Sep; 4(9):1360-5. PubMed ID: 21893499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aromatase inhibitors in breast cancer: an overview.
    Altundag K; Ibrahim NK
    Oncologist; 2006 Jun; 11(6):553-62. PubMed ID: 16794235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of nonpharmacogenetic factors in endocrine therapy.
    McCowan C; Thompson AM
    Pharmacogenomics; 2012 Apr; 13(6):721-8. PubMed ID: 22515614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer.
    Neugut AI; Zhong X; Wright JD; Accordino M; Yang J; Hershman DL
    JAMA Oncol; 2016 Oct; 2(10):1326-1332. PubMed ID: 27281650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linkage of routinely collected oncology clinical data with health insurance claims data--an example with aromatase inhibitors, tamoxifen, and all-cause mortality.
    Dore DD; Liang C; Ziyadeh N; Norman H; Bayliss M; Seeger JD
    Pharmacoepidemiol Drug Saf; 2012 May; 21 Suppl 2():29-36. PubMed ID: 22552977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM
    Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.